IDEAS home Printed from https://ideas.repec.org/a/sae/medema/v41y2021i4p476-484.html

Extrapolating Parametric Survival Models in Health Technology Assessment Using Model Averaging: A Simulation Study

Author

Listed:
  • Daniel Gallacher

    (University of Warwick, Warwick Medical School, Coventry, UK)

  • Peter Kimani

    (University of Warwick, Warwick Medical School, Coventry, UK)

  • Nigel Stallard

    (University of Warwick, Warwick Medical School, Coventry, UK)

Abstract

Previous work examined the suitability of relying on routine methods of model selection when extrapolating survival data in a health technology appraisal setting. Here we explore solutions to improve reliability of restricted mean survival time (RMST) estimates from trial data by assessing model plausibility and implementing model averaging. We compare our previous methods of selecting a model for extrapolation using the Akaike information criterion (AIC) and Bayesian information criterion (BIC). Our methods of model averaging include using equal weighting across models falling within established threshold ranges for AIC and BIC and using BIC-based weighted averages. We apply our plausibility assessment and implement model averaging to the output of our previous simulations, where 10,000 runs of 12 trial-based scenarios were examined. We demonstrate that removing implausible models from consideration reduces the mean squared error associated with the restricted mean survival time (RMST) estimate from each selection method and increases the percentage of RMST estimates that were within 10% of the RMST from the parameters of the sampling distribution. The methods of averaging were superior to selecting a single optimal extrapolation, aside from some of the exponential scenarios where BIC already selected the exponential model. The averaging methods with wide criterion-based thresholds outperformed BIC-weighted averaging in the majority of scenarios. We conclude that model averaging approaches should feature more widely in the appraisal of health technologies where extrapolation is influential and considerable uncertainty is present. Where data demonstrate complicated underlying hazard rates, funders should account for the additional uncertainty associated with these extrapolations in their decision making. Extended follow-up from trials should be encouraged and used to review prices of therapies to ensure a fair price is paid.

Suggested Citation

  • Daniel Gallacher & Peter Kimani & Nigel Stallard, 2021. "Extrapolating Parametric Survival Models in Health Technology Assessment Using Model Averaging: A Simulation Study," Medical Decision Making, , vol. 41(4), pages 476-484, May.
  • Handle: RePEc:sae:medema:v:41:y:2021:i:4:p:476-484
    DOI: 10.1177/0272989X21992297
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/0272989X21992297
    Download Restriction: no

    File URL: https://libkey.io/10.1177/0272989X21992297?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Jackson, Christopher, 2016. "flexsurv: A Platform for Parametric Survival Modeling in R," Journal of Statistical Software, Foundation for Open Access Statistics, vol. 70(i08).
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Mathyn Vervaart & Mark Strong & Karl P. Claxton & Nicky J. Welton & Torbjørn Wisløff & Eline Aas, 2022. "An Efficient Method for Computing Expected Value of Sample Information for Survival Data from an Ongoing Trial," Medical Decision Making, , vol. 42(5), pages 612-625, July.
    2. Jaclyn M. Beca & Kelvin K. W. Chan & David M. J. Naimark & Petros Pechlivanoglou, 2025. "Impact of Limited Sample Size and Follow-up on Partitioned Survival and Multistate Modeling-Based Health Economic Models: A Simulation Study," Medical Decision Making, , vol. 45(6), pages 714-725, August.
    3. Taihang Shao & Mingye Zhao & Leyi Liang & Lizheng Shi & Wenxi Tang, 2023. "Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067," PharmacoEconomics - Open, Springer, vol. 7(3), pages 383-392, May.
    4. Jean-Baptiste Trouiller & Arthur Quenéchdu & Mondher Toumi & Laurent Boyer & Philippe Laramée, 2025. "The Acceptance of Overall Survival Extrapolation Methods in Solid Tumor Treatments by Health Technology Assessment Agencies in England, France, and Australia between 2017 and 2022," Medical Decision Making, , vol. 45(8), pages 951-964, November.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Elizabeth G Bond & Lusine Abrahamyan & Mohammad K A Khan & Andrea Gershon & Murray Krahn & Ping Li & Rajibul Mian & Nicholas Mitsakakis & Mohsen Sadatsafavi & Teresa To & Petros Pechlivanoglou & for t, 2020. "Understanding resource utilization and mortality in COPD to support policy making: A microsimulation study," PLOS ONE, Public Library of Science, vol. 15(8), pages 1-16, August.
    2. Maryum Chaudhry & Martina Knappett & Vuong Nguyen & Jessica Trawin & Nathan Kenya Mugisha & Jerome Kabakyenga & Elias Kumbakumba & Shevin Jacob & J Mark Ansermino & Niranjan Kissoon & Matthew O Wiens, 2023. "Pediatric post-discharge mortality in resource-poor countries: A protocol for an updated systematic review and meta-analysis," PLOS ONE, Public Library of Science, vol. 18(2), pages 1-9, February.
    3. Oguzhan Alagoz & Prianka Singh & Matthew Dixon & Murat Kurt, 2026. "Eliciting Unreported Subgroup-Specific Survival from Aggregate Randomized Controlled Trial Data," Medical Decision Making, , vol. 46(2), pages 250-264, February.
    4. Sharples, Linda D., 2018. "The role of statistics in the era of big data: Electronic health records for healthcare research," Statistics & Probability Letters, Elsevier, vol. 136(C), pages 105-110.
    5. Suvra Pal & Hongbo Yu & Zachary D. Loucks & Ian M. Harris, 2020. "Illustration of the Flexibility of Generalized Gamma Distribution in Modeling Right Censored Survival Data: Analysis of Two Cancer Datasets," Annals of Data Science, Springer, vol. 7(1), pages 77-90, March.
    6. Burger, Rulof & Ito, Seiro, 2016. "Labour market turnovers among South African youths," IDE Discussion Papers 603, Institute of Developing Economies, Japan External Trade Organization(JETRO).
    7. Koen Degeling & Jonathan Karnon & Michiel Ven & Alan Brennan & Hendrik Koffijberg, 2025. "Discrete Event Simulation in R using the ‘Simmer’ Package for Health Economic Modelling: A Tutorial and Illustration in Colon Cancer," Applied Health Economics and Health Policy, Springer, vol. 23(6), pages 961-975, November.
    8. Jaime Leyva & Tiago Pinheiro, 2025. "Recovery, quantified: How we built a dataset of loan recovery estimates," Working Papers w202523, Banco de Portugal, Economics and Research Department.
    9. Yixin Xu & Elsa M. R. Marques & Nicky J. Welton & Linda P. Hunt & Michael Whitehouse & Ashley W. Blom & Andrew D. Beswick & Howard H. Z. Thom, 2026. "Spectrum of Models for Assessing the Cost Effectiveness of Total Knee Replacement Implants: A Comparison of Discrete-Time Cohort Markov and Continuous-Time Individual-Level Multistate Models," PharmacoEconomics, Springer, vol. 44(4), pages 477-494, April.
    10. Michael Crowther & Paul Lambert, 2016. "Multistate survival analysis in Stata," United Kingdom Stata Users' Group Meetings 2016 02, Stata Users Group.
    11. Fuino, Michel & Wagner, Joël, 2020. "Duration of long-term care: Socio-economic factors, type of care interactions and evolution," Insurance: Mathematics and Economics, Elsevier, vol. 90(C), pages 151-168.
    12. I. Oostrum & T. A. Russell-Smith & M. Jakobsson & J. Torup Østby & B. Heeg, 2022. "Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden," PharmacoEconomics - Open, Springer, vol. 6(1), pages 47-62, January.
    13. Lauren Scott & Chris Rogers, 2016. "Creating summary tables using the sumtable command," United Kingdom Stata Users' Group Meetings 2016 05, Stata Users Group.
    14. Machado, Robson J.M. & van den Hout, Ardo & Marra, Giampiero, 2021. "Penalised maximum likelihood estimation in multi-state models for interval-censored data," Computational Statistics & Data Analysis, Elsevier, vol. 153(C).
    15. Francesco Grossetti & Francesca Ieva & Anna Maria Paganoni, 2018. "A multi-state approach to patients affected by chronic heart failure," Health Care Management Science, Springer, vol. 21(2), pages 281-291, June.
    16. Matthijs M. Versteegh & Simone A. Huygens & Inigo Bermejo & Sabine Grimm & Marieke Pierik & Tessa Römkens & Fiona Schaik & Peter Wahab, 2025. "Cost–Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn’s Disease," PharmacoEconomics, Springer, vol. 43(12), pages 1405-1417, December.
    17. Gijs van de Wetering & Carolyn Owen & Versha Banerji & Ariane Gosselin & Shivani Kamdar & Nancy Paul Roc & Lytske Bakker & Gargi Ratnaparkhi & Stephane Barakat & Colin Vicente & Beenish S. Manzoor, 2026. "Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis," PharmacoEconomics - Open, Springer, vol. 10(1), pages 153-165, January.
    18. Michał Narajewski & Florian Ziel, 2019. "Estimation and Simulation of the Transaction Arrival Process in Intraday Electricity Markets," Energies, MDPI, vol. 12(23), pages 1-16, November.
    19. Caitlin Eichten & Qiufei Ma & Thomas E. Delea & May Hagiwara & Roberto Ramos & Şerban R. Iorga & Jie Zhang & Richard T. Maziarz, 2021. "Lifetime Costs for Treated Follicular Lymphoma Patients in the US," PharmacoEconomics, Springer, vol. 39(10), pages 1163-1183, October.
    20. Gabrielle Jongeneel & Marjolein J. E. Greuter & Felice N. Erning & Miriam Koopman & Jan P. Medema & Raju Kandimalla & Ajay Goel & Luis Bujanda & Gerrit A. Meijer & Remond J. A. Fijneman & Martijn G. H, 2020. "Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN)," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 1059-1073, September.

    More about this item

    Keywords

    ;
    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:medema:v:41:y:2021:i:4:p:476-484. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.